MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Cost of Revenue 2011-2026 | PCRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 185 M | 199 M | 140 M | 117 M | 107 M | 86.8 M | 87.9 M | 110 M | 71.8 M | 77.4 M | 54.8 M | 32.1 M | 16.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 16.7 M | 104 M |
Quarterly Cost of Revenue Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.3 M | 40.9 M | 34.3 M | - | 38.9 M | 44.3 M | 47.4 M | - | 39.8 M | 48.2 M | 49 M | - | 50.7 M | 50.6 M | 36.1 M | - | 34.7 M | 35.2 M | 31.3 M | 35.3 M | 30 M | 22.3 M | 29.7 M | 31.9 M | 22.3 M | 25.2 M | 27.3 M | 24 M | 19.1 M | 20.9 M | 22.9 M | 21.3 M | 18.2 M | 23.8 M | 24.6 M | 23.6 M | 43.2 M | 23.1 M | 20.3 M | 19.4 M | 15.9 M | 18.9 M | 17.6 M | 77.4 M | 20.4 M | 20 M | 18.1 M | 18.4 M | 14.8 M | 10.2 M | 11.4 M | 9.67 M | 9.29 M | 6.68 M | 6.5 M | - | 3.36 M | 3.12 M | 3.67 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.4 M | 3.12 M | 26.5 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 4.28 | 2.15 % | $ 60.2 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.15 | -4.17 % | $ 124 M |  Canada |
 |
Jupiter Wellness
JUPW
|
2.69 M | - | - | $ 33.6 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 40.48 | -2.25 % | $ 1.49 B | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
100 M | $ 5.27 | 0.96 % | $ 340 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.47 | -2.65 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.23 | 2.49 % | $ 421 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.4 | 0.42 % | $ 316 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.91 | -6.19 % | $ 3.92 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 18.04 | - | $ 116 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 1.04 | -6.31 % | $ 1.29 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 7.24 | 2.99 % | $ 286 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.56 | -4.79 % | $ 4.05 B | Canada |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.99 | -1.42 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
11 M | $ 2.29 | -2.14 % | $ 309 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 14.82 | 0.07 % | $ 17.8 B | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
57.6 M | $ 0.89 | 5.24 % | $ 32 M | USA |
 |
China Pharma Holdings
CPHI
|
4.28 M | $ 0.56 | -4.13 % | $ 2.4 M |  China |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.1 | 1.45 % | $ 24.3 M | USA |